Resistant hypertension

Versions

PDF (Español (España))
Texto (Español (España))

Keywords

Hipertensión arterial resistente
medición de la presión arterial
adherencia al tratamiento
hipertensión secundaria
medicamentos antihipertensivos Hypertension Resistant to Conventional Therapy
Blood pressure measurement
Adherence to therapy
Secondary hypertension
Antihypertensive drugs

How to Cite

Rivera Martínez, W. A., Mejía Cardona, A. F., & Valderrama Cometa , L. A. . (2023). Resistant hypertension. Interdisciplinary Journal of Epidemiology and Public Health, 5(2), e–9855. https://doi.org/10.18041/2665-427X/ijeph.2.9855 (Original work published December 30, 2022)

Abstract

Introduction: Resistant arterial hypertension is a common entity that is associated with cerebrovascular accident, coronary artery disease and mortality from all associated causes, being found in studies of disease burden in 1.5%, 2.1% and 1.6%, respectively and is also related to a deterioration of renal function.

Objective: It seeks to discuss the most important aspects of the disease, starting from the definition and pathophysiology, the criteria to achieve an early, specific diagnosis, using widely available studies and finally review the appropriate management.

Results: Multiple pathophysiological and genetic factors contribute to the development of resistant arterial hypertension. Therefore, it can have different clinical phenotypes, as well as different levels of response to antihypertensive treatment. But before choosing a specific pharmacological therapy, it is essential to make the diagnosis with a blood pressure measurement technique and appropriate conditions, ruling out the presence of pseudoresistance or secondary arterial hypertension.

Conclusion: The relationship between resistant arterial hypertension with major cardiovascular events and the development of comorbidities makes it necessary to emphasize its proper diagnosis and management by trained multidisciplinary personnel.

https://doi.org/10.18041/2665-427X/ijeph.2.9855
PDF (Español (España))
Texto (Español (España))

References

Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. doi:10.1038/s41569-021-00559-8

Lamirault G, Artifoni M, Daniel M, et al. Resistant hypertension : Novel insights. Current hypertension reviews. 2020;16(1):61-72. doi:10.2174/1573402115666191011111402

Sison J, Assaad-Khalil SH, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: The EXCITE study. Curr Med Res Opin. 2014;30(10):1937-1945. doi:10.1185/03007995.2014.942415

Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management a Scientific Statement from the American Heart Association. Vol 72.; 2018. doi:10.1161/HYP.0000000000000084

Cuenta de alto costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia 2020. Cuenta Alto Costo. 2021;152(1):1-335.

Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama. 2013;310(9):959-968. doi:10.1001/jama.2013.184182

Schargrodsky H, Hernández-Hernández R, Champagne BM, et al. CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. Am J Med. 2008;121(1):58-65. doi:10.1016/j.amjmed.2007.08.038

Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-1058. doi:10.1161/CIRCULATIONAHA.111.030189

Diaz KM, Booth JN, Calhoun DA, et al. Healthy Lifestyle Factors and Risk of Cardiovascular Events and Mortality in Treatment-Resistant Hypertension. Hypertension. 2014;64(3):465-471. doi:10.1161/hypertensionaha.114.03565

Borghi C, Tubach F, De Backer G, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. 2016;218:83-88. doi:10.1016/j.ijcard.2016.05.044

Thomas G, Xie D, Chen HY, et al. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report from the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016;67(2):387-396. doi:10.1161/HYPERTENSIONAHA.115.06487

Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004-2013. doi:10.1097/HJH.0b013e32834a8a42

Jamerson KA, Bakris GL, Dahlö B, et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press. 2007;16(2):80-86. doi:10.1080/08037050701395571

Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012-1021. doi:10.1161/HYPERTENSIONAHA.114.03850

Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-643. doi:10.1097/HJH.0000000000000051

Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105. doi:10.1136/heartjnl-2018-313599

Judd K, Calhoun A, Warnock G. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Seminars in nephrology 2014;34(5):532-539. doi:10.1016/j.semnephrol.2014.08.007

Tishkoff SA, Reed FA, Friedlaender FR, et al. The Genetic Structure and History of Africans and African Americans. 2010;324(5930):1035-1044. doi:10.1126/science.1172257

Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in African Americans and others of African descent. Int J Mol Sci. 2019;20(5):15-17. doi:10.3390/ijms20051081

Hannah-Shmouni F, Gubbi S, Spence JD, Stratakis CA, Koch CA. Resistant Hypertension: A Clinical Perspective. Endocrinol Metab Clin North Am. 2019;48(4):811-828. doi:10.1016/j.ecl.2019.08.010

Stacie D, David P, David M, Heather T, Frederick M, Karen M, Patrick O, Joe S, and Michael H. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients. Circulation. 2012; 125(13): 1635–1642. doi:10.1161/CIRCULATIONAHA.111.068064

Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019;32(1):1-3. doi:10.1093/ajh/hpy156

Bourque G, Hiremath S. Rethinking Resistant Hypertension. J Clin Med. 2022;11(5). doi:10.3390/jcm11051455

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/nejmoa1511939

Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348-354. doi:10.1111/j.1751-7176.2008.07572.x

MT K, MN H, LR B, DM L. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-96. http://www.libproxy.wvu.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=c8h&AN=107133513

Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691-697. doi:10.1161/HYPERTENSIONAHA.113.01448

AGREST A, PODESTA JJ, CUCURULLO A. Hiperaldosteronismo Primario. Medicina (B Aires). 1964;24:125-131.

Zehnder C. Hipertensión arterial renovascular. Rev Med Clin Condes. 2009;20(3):348-353. http://www.clinicalascondes.com/area-academica/pdf/MED_20_3/353HIPERTENSION.pdf

Williams B, Macdonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3

Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension the REHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681-690. doi:10.1161/HYPERTENSIONAHA.117.10662

Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164-1180. doi:10.1038/ajh.2011.171

Armario P, Oliveras A, de la Sierra A. Hipertensión arterial resistente. Hipertens y Riesgo Vasc. 2014;31(2):58-65. doi:10.1016/j.hipert.2013.12.002

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health

Downloads

Download data is not yet available.